[Introduction] Delivering clinical value with high efficiency and ushering in a new chapter of differentiated competition. Shanghai Jeyou Pharmaceutical Technology Co., Ltd. (hereinafter referred to as “Jeyou Pharmaceutical”) announced today that the National Medical Products Administration (NMPA) has officially approved the market launch of Jilemei® (suximerex sulfate tablets), the company’s independently developed KRAS G12C inhibitor. As the company’s first self-developed product since its inception, the approval of Jilemei® not only provides domestic patients with KRAS G12C-mutated non-small cell lung cancer with a new treatment option that is “once-daily, more effective, and more convenient,” but also signifies that Jeyou Pharma has successfully demonstrated its capabilities across the entire R&D process—from “molecular design” to “market approval”—laying a solid foundation for the differentiated breakthrough of its future pipeline.

(Shanghai, February 28, 2026) — At a critical juncture for the Chinese innovative drug industry’s transition toward high-quality development, Jeyou Pharma has delivered a significant achievement. The company announced that its independently developed Class 1 innovative drug, Jilemei® (generic name: soscimiresib sulfate tablets, code: JMKX001899), has received marketing approval from the NMPA for the treatment of adult patients with KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC) who have received at least one prior systemic therapy.

Addressing Clinical Pain Points: Data Demonstrates Differentiated Clinical Value

In the field of KRAS G12C inhibitors, Jile Mei® has demonstrated a highly competitive late-mover advantage through its differentiated molecular design.

Jilemei® had previously received “Breakthrough Therapy” designation from the National Medical Products Administration (NMPA). Key registration clinical data show that in the later-line treatment of advanced NSCLC patients, it demonstrated encouraging efficacy and safety: an objective response rate (ORR) as high as 55.2% and a 12-month overall survival (OS) rate of 60.4%.

In addition to superior survival benefits, Jilemei® has significantly optimized the patient experience. Its convenient dosing regimen of “twice-daily, two tablets per dose” and excellent tolerability have improved long-term treatment adherence, demonstrating the product’s highly competitive and differentiated advantages in this niche market.

Deepening Clinical Value and Actively Developing First-Line Combination Therapies

Based on a scientific understanding of resistance mechanisms, Jeyou Pharmaceuticals is actively developing first-line combination therapies pairing Jilemei® with FAK inhibitors. Currently, this combination therapy aims to overcome the challenge of monotherapy resistance through synergistic mechanisms, with the goal of further unlocking the clinical value of Jilemei® and exploring additional potential benefits for patients. The company is fully committed to advancing this combination into first-line treatment. This will not only provide a “novel oral combination therapy” for more treatment-naïve patients but is also expected to significantly expand the product’s patient population and substantially increase the future market potential of Jilemei®. This exploration, driven by clinical needs, reflects Jeyou Pharma’s pragmatic approach to continuously enhancing product longevity and benefiting patients.

Strategic Delivery: Validating Systematic R&D Capabilities from “0 to 1”

“The approval of Jile Mei® serves as a litmus test for the maturity of Jeyou Pharma’s R&D system,” said Li Zhen, President of Jeyou Pharma. “This marks not only the birth of a new drug but also a comprehensive validation of Jeyou Pharma’s ‘high-efficiency R&D system.’ From the company’s founding in 2018 to the approval of our first Class 1 new drug, we have demonstrated the team’s systematic engineering capabilities to transform scientific concepts into market-ready drugs.”

The successful execution of this end-to-end capability signifies that Jeyou Pharma has established a seamless pathway through the key stages of drug discovery, clinical development, regulatory submission, and manufacturing. This “replicable” success will significantly reduce development risks and costs for future pipeline candidates, markedly enhance the company’s R&D efficiency and management standards, and provide a robust foundation for the company to continuously deliver innovative outcomes.

Building Momentum: Leveraging Key Breakthroughs to Unlock the Value of the “3+1” Pipeline

Leveraging its robust R&D platform, Jeyou Pharma has established a “3+1” indication matrix centered on oncology, nephrology, pain, and autoimmune diseases.

Currently, Jeyou Pharma has over 40 projects in development:

(1) Commercialization Stage: One licensed product is already on the market, and one pipeline (Jile Mei®) has received formal marketing approval;

(2) Late-stage clinical: 4 pipeline candidates (covering 7 indications) are in Phase II clinical trials or the Proof of Concept (POC) stage—among them, the key indication for the core pipeline candidate JYB1904 has already initiated Phase III clinical trials;

(3) Early-stage clinical and pipeline reserves: An additional 10 projects are in Phase I clinical trials, and over 20 preclinical candidate compounds (PCCs) are under development.

The successful launch of Jile Mei® will further strengthen the confidence of capital markets and partners in Jeyou’s R&D capabilities, thereby reinvesting in this extensive R&D pipeline and creating a virtuous cycle of “one generation on the market, one generation in development, and one generation in reserve.”

Moving forward, Jeyou Pharma will continue to uphold its founding mission of “addressing unmet clinical needs through innovation.” Starting with Jilemei®, the company will accelerate the market launch of more “globally novel” drugs developed in China, striving to become a modern, innovative pharmaceutical enterprise with international influence.

About Jeyou Pharma Shanghai Jeyou Pharma Technology Co., Ltd. (hereinafter “Jeyou Pharma”), formerly the innovation platform of Jiangxi Jimin Kexin Group, has evolved into an independently operated entity and recently completed a Series A financing round of nearly 2 billion yuan. The company has assembled a strong R&D team with end-to-end capabilities covering the entire drug discovery and development process. To date, more than 10 projects in Jeyou Pharma’s proprietary pipeline have entered the clinical stage. For more information, please visit: www.jeyoupharma.com.

About Jile Mei® (JMKX001899) Jile Mei® is a highly selective KRAS G12C inhibitor independently developed by Jeyou Pharmaceuticals. Its unique molecular structure design confers excellent pharmacokinetic properties and brain penetration potential, demonstrating deep and sustained antitumor activity in clinical studies. Currently, clinical trials for this drug are underway in patients with solid tumors, including colorectal cancer with KRAS G12C mutations. In February 2026, the drug received formal marketing approval from the National Medical Products Administration (NMPA).

Media Inquiries: Shanghai Jeyou Pharmaceuticals PR Team Email: pr@jeyoupharma.com